CO6531430A2 - Tratamiento de cáncer de antagonistas notch 1 resistentes utilizando antagonistas notch3 - Google Patents

Tratamiento de cáncer de antagonistas notch 1 resistentes utilizando antagonistas notch3

Info

Publication number
CO6531430A2
CO6531430A2 CO12057624A CO12057624A CO6531430A2 CO 6531430 A2 CO6531430 A2 CO 6531430A2 CO 12057624 A CO12057624 A CO 12057624A CO 12057624 A CO12057624 A CO 12057624A CO 6531430 A2 CO6531430 A2 CO 6531430A2
Authority
CO
Colombia
Prior art keywords
notch antagonists
notch
resistors
cancer treatment
antagonists
Prior art date
Application number
CO12057624A
Other languages
English (en)
Spanish (es)
Inventor
Christian W Siebel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CO6531430A2 publication Critical patent/CO6531430A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CO12057624A 2009-09-30 2012-04-09 Tratamiento de cáncer de antagonistas notch 1 resistentes utilizando antagonistas notch3 CO6531430A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24729809P 2009-09-30 2009-09-30

Publications (1)

Publication Number Publication Date
CO6531430A2 true CO6531430A2 (es) 2012-09-28

Family

ID=43127684

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12057624A CO6531430A2 (es) 2009-09-30 2012-04-09 Tratamiento de cáncer de antagonistas notch 1 resistentes utilizando antagonistas notch3

Country Status (21)

Country Link
US (1) US9200071B2 (https=)
EP (1) EP2483311B1 (https=)
JP (3) JP6025563B2 (https=)
KR (1) KR101782180B1 (https=)
CN (1) CN102630229B (https=)
AU (1) AU2010300747A1 (https=)
BR (1) BR112012007252A2 (https=)
CA (1) CA2775880A1 (https=)
CL (1) CL2012000800A1 (https=)
CO (1) CO6531430A2 (https=)
CR (1) CR20120213A (https=)
EC (1) ECSP12011858A (https=)
ES (1) ES2580229T3 (https=)
IL (1) IL218662A0 (https=)
MA (1) MA33973B1 (https=)
MX (1) MX342250B (https=)
PE (1) PE20120998A1 (https=)
PH (1) PH12012500574A1 (https=)
RU (1) RU2012117619A (https=)
WO (1) WO2011041336A2 (https=)
ZA (1) ZA201201984B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2133796C1 (ru) * 1997-10-09 1999-07-27 ОАО "Томский электромеханический завод им.В.В.Вахрушева" Люк смотрового колодца
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
EP3431501A1 (en) 2009-06-18 2019-01-23 Pfizer Inc Anti notch-1 antibodies
AU2011342799B2 (en) 2010-12-15 2016-06-09 Wyeth Llc Anti-Notch1 antibodies
CA2890571A1 (en) 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
WO2014100435A1 (en) * 2012-12-19 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-notch3 antibodies
WO2014159242A1 (en) * 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
EP3611189A1 (en) * 2013-03-14 2020-02-19 Novartis AG Antibodies against notch 3
WO2014151606A2 (en) * 2013-03-15 2014-09-25 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
EA201691610A8 (ru) 2014-02-12 2018-05-31 Дженентек, Инк. Анти-jagged1 антитела и способы применения
CN106488775A (zh) 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
US11142573B2 (en) * 2016-04-29 2021-10-12 Aveo Pharmaceuticals, Inc. Anti-Notch3 antibody
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
PE20080891A1 (es) * 2006-10-19 2008-08-25 Genentech Inc Anticuerpos anti-notch3 y composiciones que los comprenden
RU2461569C2 (ru) 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
AU2007333805B2 (en) 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2010520280A (ja) 2007-03-05 2010-06-10 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN102112490B (zh) * 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
EP3431501A1 (en) * 2009-06-18 2019-01-23 Pfizer Inc Anti notch-1 antibodies

Also Published As

Publication number Publication date
CN102630229A (zh) 2012-08-08
WO2011041336A3 (en) 2012-05-03
WO2011041336A2 (en) 2011-04-07
JP2015145362A (ja) 2015-08-13
JP6025563B2 (ja) 2016-11-16
ECSP12011858A (es) 2012-06-29
MX342250B (es) 2016-09-22
MX2012003851A (es) 2012-05-08
KR20120100952A (ko) 2012-09-12
EP2483311A2 (en) 2012-08-08
RU2012117619A (ru) 2013-11-10
ZA201201984B (en) 2013-05-29
KR101782180B1 (ko) 2017-10-23
HK1170505A1 (en) 2013-03-01
ES2580229T3 (es) 2016-08-22
PE20120998A1 (es) 2012-08-14
CA2775880A1 (en) 2011-04-07
JP2013506675A (ja) 2013-02-28
JP2017014219A (ja) 2017-01-19
BR112012007252A2 (pt) 2020-08-11
CL2012000800A1 (es) 2012-08-31
US9200071B2 (en) 2015-12-01
AU2010300747A1 (en) 2012-04-26
CN102630229B (zh) 2015-03-04
EP2483311B1 (en) 2016-05-18
MA33973B1 (fr) 2013-02-01
PH12012500574A1 (en) 2012-10-22
US20120328608A1 (en) 2012-12-27
IL218662A0 (en) 2012-05-31
CR20120213A (es) 2012-07-09

Similar Documents

Publication Publication Date Title
CO6531430A2 (es) Tratamiento de cáncer de antagonistas notch 1 resistentes utilizando antagonistas notch3
CY1125550T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
MX373121B (es) Composiciones y metodos para el tratamiento de leucemia.
PA8740901A1 (es) Compuestos organicos
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
NI201000164A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3.
DOP2011000386A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CR20120202A (es) Métodos y composiciones para tratar cáncer
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
CU20140141A7 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas
EA201001639A1 (ru) Композиции и способы их получения и применения
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CR20160173A (es) Nuevo tratamiento de combinación para la leucemia mieloide aguda (lma)
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
CR11741A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
ITMI20091618A1 (it) Pezzo composito, nonche' impiego del pezzo composito
CL2008001658A1 (es) Composicion farmaceutica que comprende mesilato de imatinib amorfo y un principio de formulacion que estabiliza la forma amorfa; y su uso para tratar leucemia mieloide cronica avanzada y recientemente diagnosticada, leucemia mielomonocitica cronica, glioblastoma multiforme, entre otras.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
MX2009005400A (es) Metodo para el diagnostico y tratamiento del glioma.
CL2015001258A1 (es) Uso combinado de volasertib en asociacion con gcsf, fludarabina, citarabina, y uso combinado de volasertib en asociacion con gcsf, fludarabina, citarabina y citrato de daunorrubicina, para el tratamiento de la leucemia mieloide aguda (aml); composicion faramceutica.
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
MX375398B (es) Composición para la administración oral de magnesio en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.
CO6531492A2 (es) Nuevo uso antitumoral de cabazitaxel
CN301526628S (zh) 桌子

Legal Events

Date Code Title Description
FC Application refused